Generation of adoptive immune therapy against cancer in GMP conditions
Regulatory accepted 2015
Ludwig-Maximilians-University, Munich, Germany
NY-ESO-1 antigens are expressed in a variety of solid tumors but are absent in mature healthy tissues. In this study, the researchers developed a procedure to generate immune CD4C TH1 cells for the clinic targeting specifically NY-ESO-1 cancer cells. Cells were extracted from the peripheral blood of healthy donors and were then subject to in vitro sensitization by stimulating with peptides of NY-ESO-1. T cells were isolated and subsequently expanded. The manufactured cells could induce cell cycle arrest and apoptosis in tumor cell lines. The protocol is GMP grade and approved by the regulatory authorities.
Rapid generation of NY-ESO-1-specific CD4+ Thelper1 cells for adoptive T-cell therapy
Tobias Feuchtinger
Added on: 07-28-2021
[1] https://www.tandfonline.com/doi/full/10.1080/2162402X.2014.1002723[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
